Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
This is an increase over the number of companies cited in the previous quarter.
The citations in the county include:
- Process validation activities and results have not been adequately documented and adequately approved.
- Procedures for rework of nonconforming product have not been adequately established.
- Corrective and preventive action activities and/or results have not been adequately documented.
The company cited should take a voluntary action to correct its managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
AEI Technologies, Inc. | Devices | 01/29/2025 | Documentation |
AEI Technologies, Inc. | Devices | 01/29/2025 | Product rework procedures, Lack of or inadequate procedures |
AEI Technologies, Inc. | Devices | 01/29/2025 | Documentation |